ArticleScientific reports2026
Involvement of the spleen in the anti-prion activity of hydroxypropyl methylcellulose in mice.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Prion diseases are a unique group of fatal infectious neurodegenerative disorders. Previously, we reported that hydroxypropyl methylcellulose (HPMC) exerts long-term anti-prion activity in prion-infected rodents after a single peripheral administration, but the mechanism of action is not well understood. Interestingly, the distribution of HPMC in mice partially resembles that of peripheral pathogenic prions, since peripherally administered HPMC remains in the spleen and lymphoid tissues for a long period. Here, we characterized the anti-prion activity of HPMC in relation to the spleen in mice. We found that the anti-prion activity of HPMC was attenuated in mice splenectomized after intracerebral prion infection, but enhanced in mice preinflamed with thioglycolate. Furthermore, the quantity of HPMC accumulated in the spleen significantly increased in mice treated with thioglycolate. Conversely, no attenuation of the anti-prion activity of HPMC was observed in mice when other HPMC-retained organs were removed. These findings reinforce the significance of spleen in therapeutic development and suggest that spleen-associated factors are involved in the anti-prion activity of HPMC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.